*PLEASE NOTE: ALL TIMINGS LISTED AS FOLLOWS: EST | PST*

9.30 | 6.30 – Virtual Coffee Networking Morning

10.00 | 7.00 – Morning Chair’s Opening Remarks

Liquid Biopsies & Broadening Industry Applications

10.10 | 7.10 – Liquid Biopsy Assay Supporting Drug Development: Faster & Focused Enrollment

  • Carol Pena Executive Director, Translational Molecular Biomarkers and Diagnostics, Merck

Synopsis

  • Liquid biopsies to support identification of patient responders, speedy enrollment and ensure safety and efficacy in target population
  • What the successful and synchronized launch of both drug-Dx to market means for the future successes and applications of a therapeutic
  • Realizing the prognostic and predictive value of treatments via associated assays

10.40 | 7.40 – Expertise Panelist Discussion: The Additive Role of CTCs & ctDNA in Your Clinical Development Strategy

  • Joseph Schonhoft Manager, Translational Research, Epic Sciences
  • Howard I. Scher, MD, FASCO Head, Biomarker Development Program Attending Physician Department of Medicine, Memorial Sloan Kettering Cancer Center
  • Laura Sun Director, Translational Medicine & Product Development Team Lead, Harpoon Therapeutics

Synopsis

  • Complementing your biomarker evaluation with CTCs
  • Comprehensive cancer profiling: CTCs and ctDNA
  • Banking the remnant plasma and slides for future analysis

11.10 | 8.10 – Novel Biomarkers on the Horizon: Epigenetics to Detect Cancer Early

  • Ajay Goel Professor and Chair, Department of Molecular Diagnostics and Experimental Therapeutics, City of Hope

Synopsis

  • Discovery and development of new promising new biomarkers for screening and surveillance
  • Opportunities for future targeted therapy development
  • Early-detection only using ncRNAs and DNA methylation

11.40 | 8.40 – Key Lessons From the Incremental Use of Liquid Biopsy Testing in the Management & Treatment of Cancer Patients

  • Shari Brown Director of Molecular Pathology Services, NeoGenomics Laboratories

Synopsis

  • Liquid biopsy applications currently available for clinical care: the impact on our ability to deliver precision medicine
  • Clinical utility of liquid biopsy in overcoming pandemic-related barriers to cancer care
  • Liquid biopsy support for pharmaceutical clinical trials: the tangible benefits and intangible opportunities

12.10 | 9.10 – Speed Networking

12.35 | 9.35 – Event Partner Networking Break

13.00 | 11.00 – Practical Applications of ctDNA Testing for Residual Disease & Recurrence

Synopsis

• RaDaR assay has industry leading sensitivity – why is this important?
• Using residual disease and recurrence opens new options for clinical
trial design
• Data from a recent NSCLC clinical trial

13.30 | 10.30 – Longitudinal Monitoring of Melanoma Patients Receiving Checkpoint Inhibitor Immunotherapies Using Cell Free MiRNA

  • Dave Hoon Director, Center of Translational Molecular Medicine, Professor of Genomic Sequencing Center, John Wayne Cancer Institute

Synopsis

  • Profiling of cf miRNA by NGS to identify signatures in metastatic melanoma patients of stage 3 and 4
  • Identification of cf miRNA signatures that correlate to checkpoint inhibitor immunotherapy responses
  • Early detection of progression disease failure during immunotherapy failure

14.00 | 11.00 – Utility of Circulating Tumor DNA in Informing the Patient Journey

  • Priti Hedge Chief Scientific Officer, Foundation Medicine

Synopsis

  • When ctDNA can inform disease and treatment decisions
  • What it will take for ctDNA to inform the patient journey
  • Why ctDNA will not be the only option for cancer diagnostics

14.30 | 11.30 – Interactive Roundtable: New Thinking for Liquid Biopsy Approaches

With two roundtables running in parallel, pick which conversation you would like to join and contribute to alongside your peers.

Which Indications Can Learn From Successes in Oncology?

• Liquid biopsy application in oncology is seeing successes in over 10 tumor types and holds great promise for the future, can other disease areas learn from these approaches?

• Adapting technologies for detection of circulating biomarkers of similar size in indications where existing diagnosis methods are inadequate /invasive

• What does the pandemic, and response from liquid biopsy leaders, tell us about the potential clinical utility of these technologies across today’s healthcare continuum

Jean-Francois Martini, Senior Director, Translational Oncology Lead, Global Product Development Pfizer

15.10 | 12.10 – Panel Discussion: Starting With the End in Mind, Industry Collaboration for Industry Standards

  • Lauren Leiman Executive Director, BloodPAC
  • Zheng Feng Director / Head of Molecular Biomarker & Genomics, Global Clinical Biomarkers & Companion Diagnostics, EMD Serono
  • Ana Slipicevic Translational Research Director, Oncopeptides AB
  • Neeraj Adya Head of Diagnostics, Genmab

Synopsis

  • How can the industry better work together to unpick and target tumor heterogeneity?
  • What can we learn from past successful Drug-Dx collaborations?
  • Collaborations and partnering to support regulatory submission pathways

15.50 | 12.50 – Extracellular Vesicles as Emerging Liquid Biopsy Biomarkers

  • Sunitha Nagrath Associate Professor, Chemical Engineering, University of Michigan

Synopsis

  • Extracellular vesicles (EVs) are a group of heterogeneous membranebound vesicles that include exosomes, microvesicles and apoptotic bodies, which are actively secreted by almost all cell types into extracellular spaces
  • EVs contain cargo from their originating cells, including DNA, RNA and protein, which is protected by the lipid bilayer from exogenous degradation while in circulation
  • Emerging evidence has shown the role of EVs and their molecular cargo in promoting pathological processes in various diseases such as cancer and neurodegenerative diseases, with many studies linking specific EV cargo to disease progression and outlook

16.20 | 13.20 – Chair’s Closing Remarks: What’s Next For Liquid Biopsy in Precision Oncology

Synopsis

  • What new opportunities are there for liquid biopsies to further precision therapy approaches in oncology
  • What does clinical evidence show us in terms of liquid biopsy replacing the ‘gold standard’ become a reality in some instances – (Drawing on case study examples)
  • Reflecting on the core challenges industry needs to solve

16.30 | 13.30 – Networking & End of Day Two